A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).Ting Wang, Qing Zhou, Lin Huang et al.|Journal of Clinical Oncology|2024Cited by 3